Journal article · 2025 · Open access
Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries
Arthritis & Rheumatology, 77(9), 1194–1204 · Published 15 April 2025 · DOI 10.1002/art.43188
In brief
“Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries” is a 2025 journal article by Romain Aymon and 28 co-authors, published in Arthritis & Rheumatology. OpenAlex counts 33 citations as of 19 November 2026, which puts it in the top 2% of works published in 2025 by citations. It is open access under a CC BY-NC licence: the full text is free to read at Arthritis & Rheumatology.
- Citations
- 33
- Most cited in
- 2026 (25)
- Field-weighted impact
- 16.62
- References
- 26
- Authors
- 29
Abstract
OBJECTIVE: Our objective was to assess the incidence of major adverse cardiovascular events (MACEs) in patients with rheumatoid arthritis (RA) treated with JAK inhibitors (JAKi), tumor necrosis factor inhibitors (TNFi), or biologic disease-modifying antirheumatic drugs with other modes of action (bDMARD-OMA) in a multicountry, real-world population. METHODS: Patients with RA from 15 registries in the JAK-pot collaboration were included. MACE incidence was analyzed using two approaches: a within-registry analysis aggregating country-specific estimates from registers with >25 incident MACEs through meta-analysis and an individual-level data combined analysis. We used adjusted linear mixed Poisson regression to obtain incidence rate ratios (IRRs) of MACEs between treatment groups, accounting for multiple treatment courses. RESULTS: The study included 73,008 treatment courses (16,417 JAKi, 35,373 TNFi, and 21,218 bDMARD-OMA) and 828 incident MACEs among 51,233 patients. Median follow-up time was 1.3 years, with most of the follow-up concentrated in the first two years of treatment. Incidence rates were 7.0, 7.6, and 11.8 per 1,000 person-years for JAKi, TNFi, and bDMARD-OMA, respectively. Compared to TNFi, JAKi (within-registry adjusted IRR 0.89, 95% confidence interval [CI] 0.63-1.25) had similar incidence rates of MACEs and bDMARD-OMA had higher rates (within-registry adjusted IRR 1.35, 95% CI 1.10-1.66). Combined analysis showed similar results. CONCLUSION: Observational data from the JAK-pot collaboration show no evidence of an increase in cardiovascular events during the first two years of use with JAKi compared to TNFi in the general RA population.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Aymon, R., Mongin, D., Guemara, R., Salis, Z., Askling, J., Choquette, D., Codreanu, C., Di Giuseppe, D., Flouri, I. D., Huschek, D., Hyrich, K. L., Iannone, F., Kvien, T. K., Leeb, B. F., Nordström, D., Varela, L. O., Pavelká, K., Pombo‐Suárez, M., Rodrigues, A. M., . . . Lauper, K. (2025). Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries. Arthritis & Rheumatology, 77(9), 1194–1204. https://doi.org/10.1002/art.43188
MLA 9
Aymon, Romain, et al. “Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries.” Arthritis & Rheumatology, vol. 77, no. 9, 2025, pp. 1194–1204. https://doi.org/10.1002/art.43188.
Chicago
Aymon, Romain, Denis Mongin, Romain Guemara, Zübeyir Salis, Johan Askling, D. Choquette, Cătălin Codreanu, et al. 2025. “Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries.” Arthritis & Rheumatology 77 (9): 1194–1204. https://doi.org/10.1002/art.43188.
Harvard
Aymon, R. et al. (2025) ‘Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries’, Arthritis & Rheumatology, 77(9), pp. 1194–1204. doi:10.1002/art.43188.
IEEE
R. Aymon et al., “Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries,” Arthritis & Rheumatology, vol. 77, no. 9, pp. 1194–1204, 2025, doi: 10.1002/art.43188.
BibTeX
@article{aymon2025incidence,
title = {{Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries}},
author = {Aymon, Romain and Mongin, Denis and Guemara, Romain and Salis, Zübeyir and Askling, Johan and Choquette, D. and Codreanu, Cătălin and Di Giuseppe, Daniela and Flouri, Irini D. and Huschek, Doreen and Hyrich, Kimme Leanne and Iannone, Florenzo and Kvien, Tore Kristian and Leeb, Burkhard F. and Nordström, Dan and Varela, Lucia Otero and Pavelká, Karel and Pombo‐Suárez, Manuel and Rodrigues, Ana Maria and Rotar, Žiga and Sidiropoulos, Prodromos I. and Provan, Sella Aarrestad and Strangfeld, Anja and Trokovic, Nina and Závada, Jakub and Kearsley‐Fleet, Lianne and Courvoisier, Delphine Sophie and Finckh, Axel and Lauper, Kim},
journal = {Arthritis \& Rheumatology},
year = {2025},
volume = {77},
number = {9},
pages = {1194--1204},
doi = {10.1002/art.43188},
url = {https://doi.org/10.1002/art.43188}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- rheumatoid arthritis
- JAK inhibitors
- major adverse cardiovascular events
- tumor necrosis factor inhibitors
- biologic DMARDs
- cardiovascular safety
- incidence rate ratio
- real-world evidence
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Aymon, R., Mongin, D., Guemara, R., Salis, Z., Askling, J., Choquette, D., Codreanu, C., Di Giuseppe, D., Flouri, I. D., Huschek, D., Hyrich, K. L., Iannone, F., Kvien, T. K., Leeb, B. F., Nordström, D., Varela, L. O., Pavelká, K., Pombo‐Suárez, M., Rodrigues, A. M., . . . Lauper, K. (2025). Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries. Arthritis & Rheumatology, 77(9), 1194–1204. https://doi.org/10.1002/art.43188
How many times has this paper been cited?
33 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Arthritis & Rheumatology: sign in and open the PDF from this page.
Who wrote this paper?
Romain Aymon, Denis Mongin, Romain Guemara, Zübeyir Salis, Johan Askling, D. Choquette, Cătălin Codreanu, Daniela Di Giuseppe, Irini D. Flouri, Doreen Huschek, Kimme Leanne Hyrich, Florenzo Iannone and 17 more.
What is the DOI of this paper?
10.1002/art.43188, permanently at https://doi.org/10.1002/art.43188. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.